Document:

Exhibit 10.6

 

PLACEMENT AGENT WARRANT

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

 

	No. _________	Issue Date: _________________, 2013
	 	 

NEUROTROPE, INC.

Series
A Preferred Stock Purchase Warrant

_________________

 

THIS CERTIFIES THAT,
for value received, [            ], or [his/her/its] registered assigns (the “Holder”), is entitled to subscribe
for and purchase from Neurotrope, Inc., a Nevada corporation (the “Company”), at any time prior to 5:00 p.m.,
Eastern time, on ________________, the Shares at the Exercise Price (each as defined in Section 1 below).

 

This Warrant is subject to the following
terms and conditions:

 

1. Shares.
The Holder has, subject to the terms set forth herein, the right to purchase, at any time during the Warrant Exercise Term,
up to [            ] ( ) shares (the
“Shares” or the “Warrant Shares”) of Series A Convertible Preferred Stock, par value
$0.0001, of the Company (“Series A Preferred Stock”), at a per share exercise price of $________ (the
“Exercise Price”). The Exercise Price is subject to adjustment as provided in Section 3 hereof.

 

2.  Exercise
of Warrant.

 

(a)Exercise for
Cash. This Warrant may be exercised by the Holder at any time during the Warrant Exercise Term, in whole or in part, by delivering
the notice of exercise attached as Exhibit A hereto (the “Notice of Exercise”), duly executed by the
Holder to the Company at its principal office, or at such other office as the Company may designate, accompanied by payment, in
cash or by wire transfer of immediately available funds or by check payable to the order of the Company, of the amount obtained
by multiplying the number of Shares designated in the Notice of Exercise by the Exercise Price (the “Purchase Price”).
For purposes hereof, “Exercise Date” shall mean the date on which all deliveries required to be made to the
Company upon exercise of this Warrant pursuant to this Section 2(a) shall have been made.

 

(b)Cashless Exercise.
In addition to the provisions of Section 2(a) above, at any time, the Holder may, in its sole discretion, exercise all or any part
of this Warrant in a “cashless” or “net-issue” exercise (a “Cashless Exercise”) by delivering
to the Company (1) the Notice of Exercise and (2) the original Warrant, pursuant to which the Holder shall surrender the right
to receive upon exercise of this Warrant the full number of Warrant Shares set forth in Section 1 hereof and instead, without cash
payment, shall receive a number of Warrant Shares calculated by using the following formula:

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
1

    	 

    

 

	 	X 	=  	Y  (A - B)	 
	 	 	 	A	 
	 	 	 	 	 
	with:  	X =   	the number of Warrant Shares to be issued to the Holder
	 	 	 
	 	Y =	the number of Warrant Shares with respect to which the Warrant is being exercised
	 	 	 	 	 
	 	A =	the fair value per share of Series A Preferred Stock on the date of exercise of this Warrant
	 	 	 	 	 
	 	B =	the then-current Exercise Price of the Warrant

 

Solely for the purposes
of this paragraph, “fair value” per share of Series A Preferred Stock shall mean (A) the average of the closing sales
prices, as quoted on the primary national or regional stock exchange on which the Series A Preferred Stock is listed, or, if not
listed, on the Nasdaq Market if quoted thereon, or, if not listed or quoted, the OTC Bulletin Board (or any tier of the OTC Markets)
if quoted thereon, on the twenty (20) trading days immediately preceding the date on which the Notice of Exercise is deemed to
have been sent to the Company, or (B) if the Series A Preferred Stock is not publicly traded as set forth above, as reasonably
and in good faith determined by the Board of Directors of the Company as of the date which the Notice of Exercise is deemed to
have been sent to the Company.

 

For purposes of Rule
144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a cashless
exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for such shares shall be deemed
to have commenced, on the date this Warrant was originally issued.

 

(c)Issuance of
Certificates. As soon as practicable after the exercise of this Warrant, in whole or in part, in accordance with Section 2(a)
or (b) hereof, the Company, at its expense, shall cause to be issued in the name of and delivered to the Holder (i) a certificate
or certificates for the number of fully paid and non-assessable Shares to which the Holder shall be entitled upon such exercise
and, if applicable, (ii) a new warrant of like tenor to purchase all of the Shares that may be purchased pursuant to the portion,
if any, of this Warrant not exercised by the Holder. The Holder shall for all purposes hereof be deemed to have become the Holder
of record of such Shares on the date on which the Notice of Exercise and payment of the Purchase Price in accordance with Section
2(a) were delivered and made or the date of notice of cashless exercise in accordance with Section 2(b) hereof, respectively, irrespective
of the date of delivery of such certificate or certificates, except that if the date of such delivery, notice and payment is a
date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of record of
such Shares at the close of business on the next succeeding date on which the stock transfer books are open.

 

(d)Taxes.
The issuance of the Shares upon the exercise of this Warrant, and the delivery of certificates or other instruments representing
such Shares, shall be made without charge to the Holder for any tax or other charge of whatever nature in respect of such issuance
and the Company shall bear any such taxes in respect of such issuance.

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
2

    	 

    

 

3.Adjustment
of Exercise Price and Number of Shares.

 

(a)Adjustment
for Reclassification, Consolidation or Merger. If while this Warrant, or any portion hereof, remains outstanding and unexpired
there shall be (i) a reorganization or recapitalization (other than a combination, reclassification, exchange or subdivision of
shares otherwise provided for herein), (ii) a merger or consolidation of the Company with or into another corporation or other
entity in which the Company shall not be the surviving entity, or a reverse merger in which the Company shall be the surviving
entity but the shares of the Company’s capital stock outstanding immediately prior to the merger are converted by virtue
of the merger into other property, whether in the form of securities, cash or otherwise, or (iii) a sale or transfer of the Company’s
properties and assets as, or substantially as, an entirety to any other corporation or other entity in one transaction or a series
of related transactions, then, as a part of such reorganization, recapitalization, merger, consolidation, sale or transfer, unless
otherwise directed by the Holder, all necessary or appropriate lawful provisions shall be made so that the Holder shall thereafter
be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price
then in effect, the greatest number of shares of capital stock or other securities or property that a holder of the Shares deliverable
upon exercise of this Warrant would have been entitled to receive in such reorganization, recapitalization, merger, consolidation,
sale or transfer if this Warrant had been exercised immediately prior to such reorganization, recapitalization, merger, consolidation,
sale or transfer, all subject to further adjustment as provided in this Section 3. If the per share consideration payable to the
Holder for Shares in connection with any such transaction is in a form other than cash or marketable securities, then the value
of such consideration shall be determined in good faith by the Company’s Board of Directors (the “Board of Directors”).
The foregoing provisions of this paragraph shall similarly apply to successive reorganizations, recapitalizations, mergers, consolidations,
sales and transfers and to the capital stock or securities of any other corporation that are at the time receivable upon the exercise
of this Warrant. In all events, appropriate adjustment shall be made in the application of the provisions of this Warrant with
respect to the rights and interests of the Holder after the transaction, to the end that the provisions of this Warrant shall be
applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable or issuable
after such reorganization, recapitalization, merger, consolidation, sale or transfer upon exercise of this Warrant.

 

(b)Adjustments
for Split, Subdivision or Combination of Shares. If the Company shall at any time subdivide (by any stock split, stock dividend,
recapitalization, reorganization, reclassification or otherwise) the shares of Series A Preferred Stock subject to acquisition
hereunder, then, after the date of record for effecting such subdivision, the Exercise Price in effect immediately prior to such
subdivision will be proportionately reduced and the number of shares of Series A Preferred Stock subject to acquisition upon exercise
of the Warrant will be proportionately increased. If the Company at any time combines (by reverse stock split, recapitalization,
reorganization, reclassification or otherwise) the shares of Series A Preferred Stock subject to acquisition hereunder, then, after
the record date for effecting such combination, the Exercise Price in effect immediately prior to such combination will be proportionately
increased and the number of shares of Series A Preferred Stock subject to acquisition upon exercise of the Warrant will be proportionately
decreased.

 

(c)Adjustments
for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof, remains outstanding and
unexpired, the holders of any class of securities as to which purchase rights under this Warrant exist at the time shall have received
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend,
then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of such class of
security receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of
such other or additional stock or other securities or property (other than cash) of the Company that such holder would hold on
the date of such exercise had it been the holder of record of the class of security receivable upon exercise of this Warrant on
the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained
such shares and/or all other additional stock available to it as aforesaid during said period, giving effect to all adjustments
called for during such period by the provisions of this Section 3.

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
3

    	 

    

 

(d)Notice of Adjustments.
Upon any adjustment of the Exercise Price and any increase or decrease in the number of Shares purchasable upon the exercise of
this Warrant, then, and in each such case, the Company, within 30 days thereafter, shall give written notice thereof to the Holder
at the address of such Holder as shown on the books of the Company, which notice shall state the Exercise Price as adjusted and,
if applicable, the increased or decreased number of Shares purchasable upon the exercise of this Warrant, setting forth in reasonable
detail the method of calculation of each.

 

4.Notices.
All notices, requests, consents and other communications required or permitted under this Warrant shall be in writing and shall
be deemed delivered (i) three business days after being sent by registered or certified mail, return receipt requested, postage
prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business
day delivery or (iii) on the business day of delivery if sent by facsimile transmission, in each case to the intended recipient
as set forth below:

 

If to the Company
to:

 

Neurotrope,
Inc.

10732 Hawk’s
Vista St.

Plantation,
FL 33324

Attn: Dr.
James New

 

Facsimile:
__________

 

With a copy (that shall
not constitute notice) to:

 

Bilzin Sumberg Baena Price &
Axelrod LLP

1450 Brickell Ave, 23rd Floor

Miami, FL 33131

Attention: Laura Vaughn

Facsimile: 305-351-2286

 

If to the Holder
to:

 

The contact information

listed on the attached

Warrant Contact Information Sheet

 

Either party may give
any notice, request, consent or other communication under this Warrant using any other means (including personal delivery, messenger
service, facsimile transmission, first class mail or electronic mail), but no such notice, request, consent or other communication
shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Either party
may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the
other party notice in the manner set forth in this Section 4.

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
4

    	 

    

 

5.Legends.
Each certificate evidencing the Shares issued upon exercise of this Warrant shall be stamped or imprinted with a legend substantially
in the following form:

 

THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES
LAWS OF ANY STATE AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL
AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

6.Removal of
Legend. Upon request of a holder of a certificate with the legends required by Section 5 hereof, the Company shall issue to
such holder a new certificate therefor free of any transfer legend, if, with such request, the Company shall have received an opinion
of counsel satisfactory to the Company in form and substance to the effect that any transfer by such holder of the Shares evidenced
by such certificate will not violate the Act or any applicable state securities laws.

 

7.Fractional
Shares. No fractional Shares will be issued in connection with any exercise hereunder. Instead, the Company shall round up,
as nearly as practicable to the nearest whole Share, the number of Shares to be issued.

 

8.Rights of
Stockholders. Except as expressly provided in Section 3(c) hereof, the Holder, as such, shall not be entitled to vote or receive
dividends or be deemed the holder of the Shares or any other securities of the Company that may at any time be issuable on the
exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the
rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of
stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of
meetings, or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have
been issued, as provided herein.

 

9.Transfers
and Assignments. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may
be transferred by any registered holder hereof (a “Transferor”). On the surrender for exchange of this Warrant,
with the Transferor's endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”)
and together with an opinion of counsel reasonably satisfactory to the Company that the transfer of this Warrant will be in compliance
with applicable securities laws, the Company will issue and deliver to or on the order of the Transferor thereof a new Warrant
or Warrants of like tenor, in the name of the Transferor and/or the transferee(s) specified in such Transferor Endorsement Form
(each a “Transferee”), calling in the aggregate on the face or faces thereof for the number of shares of Series
A Preferred Stock called for on the face or faces of the Warrant so surrendered by the Transferor.

 

10.Miscellaneous.

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
5

    	 

    

 

(a)This Warrant
and disputes arising hereunder shall be governed by and construed and enforced in accordance with the laws of the State of Nevada
applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules.

 

(b)The headings
in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

(c)The covenants
of the respective parties contained herein shall survive the execution and delivery of this Warrant.

 

(d)The terms of
this Warrant shall be binding upon and shall inure to the benefit of any successors or permitted assigns of the Company and of
the Holder and of the Shares issued or issuable upon the exercise hereof.

 

(e)This Warrant
and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties
with regard to the subject hereof.

 

(f)The Company
shall not, by amendment of the Certificate of Incorporation or Bylaws, or through any other means, directly or indirectly, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant and shall at all times in good faith assist
in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect
the rights of the Holder contained herein against impairment.

 

(g)Upon receipt
of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case
of any such loss, theft or destruction, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the
Company, or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Company, at its expense,
will execute and deliver to the Holder, in lieu thereof, a new Warrant of like date and tenor.

 

(h)This Warrant
and any provision hereof may be amended, waived or terminated only by an instrument in writing signed by the Company and the Holder.

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be signed by its duly authorized officer.

 

	 	NEUROTROPE, INC.
	 	 	 
	 	 	 
	 	 	 
	 	By:  	 
	 	 	Name: 
	 	 	Title:   

  

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
6

    	 

    

 

WARRANT CONTACT INFORMATION SHEET

 

 

Holder Name: _______________________________________________

 

Address: ____________________________________________________________________________

 

Fax Number: __________________________

 

Email: _______________________________

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
7

    	 

    

 

Exhibit A

NOTICE OF EXERCISE

 

		TO:	Neurotrope, Inc.

		 	Attention: President

 

The undersigned hereby
elects to purchase _______________ shares (the “Shares”) of Series A Preferred Stock of Neurotrope, Inc. (the “Company”)
pursuant to the terms of the attached Warrant, and delivers herewith:

 

(1)$______________
(in cash as provided for in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant to such Warrant;
and

 

(2)_______________
shares of Series A Preferred Stock underlying the attached Warrant (pursuant to a Cashless Exercise in accordance with Section
2(b) of the Warrant) (check here if the undersigned desires to deliver a Warrant for an unspecified number of shares equal to the
number sufficient to effect a Cashless Exercise [___]).

 

Please issue a certificate
or certificates representing said shares in the name of the undersigned or in such other name as is specified below:

 

	 	(Name)	 
	 	 	 
	 	 	 
	 	(Address)	 

 

If the shares issuable upon this exercise
of the Warrant are not all of the Shares which the Holder is entitled to acquire upon the exercise of the Warrant, the undersigned
requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered to:

 

	 	(Name)	 
	 	 	 
	 	 	 
	 	(Address)	 

 

The undersigned
hereby represents and warrants the following:

 

(a) He/she/it has
such knowledge and experience in financial and business affairs that he/she/it is capable of evaluating the merits and risks involved
in purchasing the Shares, (ii) is able to bear the economic risks involved in purchasing the Shares, and (iii) is an “accredited
investor,” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended;

 

(b)In making the
decision to purchase the Shares, he/she/it has relied solely on independent investigations made by it and has had the opportunity
to ask questions of, and receive answers from, the Company concerning the Shares, the financial condition, prospective business
and operations of the Company and has otherwise had an opportunity to obtain any additional information, to the extent that the
Company possess such information or could acquire it without unreasonable effort or expense;

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
A-1

    	 

    

 

(c) The overall
commitment of the undersigned to investments that are not readily marketable is not disproportionate to his/hers/its net worth
and income, and the purchase/acquisition of the Shares will not cause such overall commitment to become disproportionate; it can
afford to bear the loss of the purchase price of the Shares;

 

(d)He/she/it has
no present need for liquidity in its investment in the Shares; and

 

(e)He/she/it acknowledges
that the transaction contemplated in connection with the purchase/acquisition of the Shares has not been reviewed or approved by
the Securities and Exchange Commission or by any administrative agency charged with the administration of the securities laws of
any state, and that no such agency has passed on or made any recommendation or endorsement of any of the securities contemplated
hereby.

 

	 	(Signature and Date)
	 	 
	 	Name (print):  	 

 

    	{Exhibit 10.6  - Form of Placement Warrant Series A.1 /}
A-2

    	 

    

 

Exhibit B

 

FORM OF TRANSFEROR ENDORSEMENT

(To be signed only on transfer of Warrant)

 

FOR VALUE RECEIVED,
the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees”
the right represented by the within Warrant to purchase the percentage and number of shares of Series A Preferred Stock of NEUROTROPE,
INC. to which the within Warrant relates specified under the headings “Percentage Transferred” and “Number Transferred,”
respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on
the books of NEUROTROPE, INC. with full power of substitution in the premises.

 

	Transferees	Percentage Transferred	Number Transferred
	 	 	 
	 	 	 
	 	 	 

 

If the total of the Shares are not all
of the Shares evidenced by the foregoing Warrant, the undersigned Transferor requests that a new Warrant evidencing the right to
acquire the Shares not so transferred assigned be issued in the name of and delivered to the undersigned Transferor.

 

	Dated:  __________________, _______	 	 
	 	 	
        (Signature must conform to name of holder 

         as specified on the face
        of the Warrant)

	 	 	 
	Signed in the presence of:	 	 
	 	 	 
	 	 	 
	(Name)	 	(Address)
	 	 	 
	
        ACCEPTED AND AGREED:

        [TRANSFEREE]
	 	 
		 	 
	 	 	 
	 	 	 
	(Name)	 	(Address)

 

    	{Exhibit 10.6 - Form of Placement Warrant Series A.1 /}
B-1Exhibit 10.7

 

 

Member FINRA, SIPC

 

PLACEMENT AGREEMENT

  

June 25, 2013

 

EDI Financial, Inc.

12221 Merit Drive, Suite 1020

Dallas, TX 75251

 

Re: Private placement offering
of $6,865,000 of Series A Convertible Preferred Stock (“Offering”), of Neurotrope Bioscience, Inc. 

 

Dear Sirs:

 

Neurotrope Bioscience,
Inc., a Delaware corporation (“Neurotrope” or the “Company”) proposes to offer, offer for sale and
sell $6,865,000 (the "Offering Amount") of shares of Neurotrope Series A Convertible Preferred Stock, par value $.001
per share (the “Series A Preferred Stock”, and collectively with the shares of Company common stock, par value $.001
per share (the “Common Stock”) underlying the Series A Preferred Stock, the “Securities”) to accredited
investors in accordance with one or more exemptions from the registration requirements of the Securities Act of 1933, as amended
(the "Securities Act"). The Company and the Placement Agent (as defined below) may, upon their mutual agreement, accept
additional subscriptions of up to an additional $2,750,000 (the “Over-allotment”). Further, this Over-allotment may
be increased upon the mutual agreement of the Company and the Placement Agent. The Series A Preferred Stock will be offered at
a price per share to be mutually determined by the Company and the Placement Agent and set forth in the Memorandum (as defined
below).

 

The Company and the
Securities are to be more fully described in a private placement memorandum completed by EDI Financial, Inc. (the “Placement
Agent”) and agreed to and approved by the Company prior to commencement of the Offering (together with any exhibits, supplements
or amendments thereto, collectively, the “Memorandum”). Neither the Placement Agent nor any Participating Dealers (as
defined below) shall distribute the Memorandum or other materials regarding the Company unless the Company has reviewed and approved,
in writing, such Memorandum or other materials in advance of such distribution.

 

The Company desires
to employ Placement Agent as its placement agent to offer, offer for sale and sell the Series A Preferred Stock subject to all
of the terms and conditions of this Placement Agreement (“Agreement”) and subject to the terms and conditions contained
in the Memorandum.

 

 1.                     Description of Offering and Appointment of Agent.

 

(a)Appointment. On the basis
of the representations, warranties and covenants herein contained, but subject to the terms and conditions herein set forth, the
Placement Agent is hereby appointed an exclusive agent of the Company during the Offering Period (as defined herein) for the purpose
of finding subscribers for sale of the Offering Amount on an “best efforts/” basis and for sale of the Over-allotment
(including any increase thereto), on a "best efforts" basis only upon mutual agreement of the Company and the Placement
Agent. The Placement Agent may, in its sole discretion, appoint participating broker-dealers who are members in good standing
of the Financial Industry Regulatory Authority, Inc. (“FINRA”) to offer and sell the Series A Preferred Stock (the
“Participating Dealers”) pursuant to a dealer agreement between the Placement Agent and each Participating Dealer
(“Dealer Agreement”). Each Dealer Agreement shall contain representations, warranties and covenants of the Participating
Dealer that are substantially equivalent to the representations, warranties and covenants of the Placement Agent set forth in
this Agreement. A minimum purchase of $250,000 per investor is required, provided the Company may, in its sole discretion, accept
subscriptions for less than this amount. As further set forth in Section 7(b)(1), the Placement Agent acknowledges that the Company
may limit its acceptance of subscriptions and may reject any subscription in its sole and absolute discretion, and the Placement
Agent agrees that any such rejection of a subscription obtained by the Placement Agent or by the Participating Dealers shall be
deemed not to be a sale made by the Placement Agent or by the Participating Dealers.

 

    	 

    	 

    

 

(b)Offering Period. The
“Offering Period” shall mean that period during which the shares of Series A Preferred Stock are offered for sale,
commencing on the date of the Memorandum and continuing until the earliest to occur of (i) the date upon which subscriptions for
the Offering Amount and the Over-allotment, if so agreed by the Company and the Placement Agent, have been accepted; (ii) July
31, 2013, which period may be extended by mutual agreement of the Company and the Placement Agent for up to an additional 30 days;
or (iii) the date upon which the Placement Agent and the Company elect to terminate the Offering.

 

(c)Acceptance. The Placement
Agent hereby accepts such agency and agrees on the terms and conditions herein set forth to use the Placement Agent's best efforts
during the Offering Period to find subscribers for the Series A Preferred Stock.

 

(d)Private Placement Offering.
The Offering will not be registered under federal securities laws or the securities laws of any state. The Company will rely
upon exemptions from registration under federal securities laws and state securities acts (the “State Acts”). With
respect to federal securities laws, the Company will rely on one or more exemptions from registration for sales to accredited investors
(as defined in Section 2(15) of the Securities Act and Rule 501 promulgated thereunder), including, without limitation, exemptions
from registration provided by Section 4(2) of the Securities Act, Rule 506 of Regulation D and/or Regulation S, promulgated as
part of the rules and regulations under the Securities Act (the “Rules and Regulations”). The Company shall use its
best efforts to exempt the Securities from qualification or registration under the State Acts as reasonably requested by the Placement
Agent and shall make such filings under the State Acts as may be necessary if exemptions from qualification or registration are
unavailable. The Company or its counsel shall provide Placement Agent with all applications, forms and documents filed in each
jurisdiction where the Securities are to be offered. The Offering shall be at the offering price and upon the terms and conditions
set forth in the Memorandum and the subscription documents to be delivered with the Memorandum, and on the basis of the representations
and warranties therein contained, and subject to the terms and conditions herein set forth.

 

(e)Subscription Procedures and
Closing. The Company and the Placement Agent each agree that all subscribers will be instructed to deliver their subscription
funds to a segregated escrow account (the “Escrow Account”) maintained by the Placement Agent at U.S. Bank National
Association, a national bank (“Escrow Agent”). Subscribers’ wires shall be delivered directly to the Escrow Account,
and subscribers’ checks shall be made payable to the Escrow Account and delivered to the Placement Agent for deposit to the
Escrow Account. All subscribers' checks will be transmitted directly to the Escrow Agent or, if applicable, returned to subscriber,
by noon of the next business day after receipt by the Placement Agent. The Placement Agent shall be responsible for collecting
all executed subscription documents. Upon the Company’s acceptance of subscriptions in an aggregate amount of at least the
Offering Amount, a closing will take place at the offices of the Company's legal counsel or another location as determined by the
Company (including closing by remote electronic means), and the Escrow Agent shall disburse funds from the Escrow Account to the
Company upon the written direction signed by the Placement Agent and the Company (“the Closing”). Promptly following
the Closing, certificates evidencing the Securities sold in the Offering will be duly executed and issued by the Company, if applicable,
in accordance with the terms of the Memorandum and delivered to the investors. Any funds deposited to the Escrow Account in payment
of a rejected subscription, or portion thereof, or any funds received after the termination of the Offering Period, shall be promptly
returned to the subscriber from which such funds were received, without interest or deduction.

 

    	 

    	 

    

 

(f)Other
Covenants. In connection with the Offering, the Company and Placement Agent each agree as follows: (i) the Series A Preferred
Stock will be offered and sold only to accredited investors pursuant to the registration exemption provided by Section 4(2) of
the Securities Act , Rule 506 of Regulation D and/or Regulation S, as and to the extent applicable to the Offering, and will otherwise
comply with the applicable laws and regulations of any jurisdictions in which the Series A Preferred Stock are offered or sold,
(ii) neither the offer, sale nor delivery of the Series A Preferred Stock in conformity with the terms hereof will violate Section 5
of the Securities Act, as currently in effect, and (iii) neither the Company nor Placement Agent has taken, nor will either party
take any action which conflicts with the conditions and requirements of, or which would make unavailable with respect to the sale
of the Series A Preferred Stock, the exemptions from registration available pursuant to Rule 506 of Regulation D, Regulation
S and/or Section 4(2) of the Securities Act and neither the Company nor Placement Agent knows of any reason why any such exemption
would be otherwise unavailable to it.

 

(g)Information to be Supplied.
The Company will furnish or cause to be furnished to Placement Agent such information as Placement Agent reasonably believes appropriate
to its assignment or necessary in connection with its preparation of, review of, or inclusion in, the Memorandum. It is also understood
that the Company may make available to Placement Agent and the offerees of the Series A Preferred Stock additional material, data
or other information relating to the Company to the extent such information can be obtained without unreasonable effort or expense
and is not otherwise confidential or a trade secret of the Company (collectively, as limited the “Company Data”). The
Company recognizes and confirms that (a) in performing the services contemplated by this Agreement, Placement Agent will use
and rely primarily on the Company Data made available to Placement Agent and on other information available from generally recognized
public sources without having independently verified the same; (b) the contents of the Company Data are the sole responsibility
of the Company, and Placement Agent does not assume any responsibility for the accuracy or completeness of the Company Data, and
will not undertake to verify independently any of their accuracy or completeness; and (c) Placement Agent will furnish a copy
of the Memorandum, and each supplement or amendment thereto, to each purchaser of Series A Preferred Stock, and Placement Agent
will not employ any written material other than the Memorandum, each supplement and amendment thereto and the Company Data.

 

2.                 
   Representations and Warranties of the Company. The Company represents and warrants to, and agrees with,
the Placement Agent and the Participating Dealers (if any) as follows:

 

(a)The Company is a corporation
duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it was formed, with all requisite
power and authority to enter into this Agreement and to carry out its obligations hereunder.

 

(b)The Company has complied
or will comply with Section 4(2) of the Securities Act, with all of the provisions of the Rules and Regulations promulgated under
the Securities Act, specifically including the provisions of Regulation D and Rule 506 thereunder and/or Regulation S, applicable
to it in connection with the offering and sale of the Series A Preferred Stock, and with all States Acts and regulations applicable
to it in connection with the offering and the sale of the Series A Preferred Stock.

 

(c)The execution of this
Agreement, and the employment of the Placement Agent, have been duly authorized by the Company and, at the time of its execution
and performance, this Agreement shall not constitute or result in any breach or violation (other than any breach or violation which
shall have been waived or consented to in writing) of any of the terms, provisions or conditions of, or constitute a default under,
any material indenture, mortgage, deed of trust, note, contract, commitment, instrument or document to which it or any of its properties
is subject, the Articles of Incorporation or Bylaws or corresponding documents of the Company, or any order, arbitration award,
or judgment, of any court or governmental agency or body having jurisdiction over the Company or any of its activities or properties;
and no consent, approval, authorization or order of any court or governmental agency or body is required for the consummation of
the transactions contemplated hereby.

 

(d)The Securities shall
be duly authorized and shall be validly issued, and shall conform to the description thereof contained in the Memorandum.

 

(e)The Company has not been
subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily or permanently enjoining
such person for failing to comply with Section 503 of Regulation D.

 

(f)The Company represents
and warrants that at all times from the respective dates that the final form of the Memorandum, which has been approved by the
Company for distribution to prospective investors, is furnished or made available by the Company to Placement Agent or, either
directly or through Placement Agent or Participating Dealers, to offerees or any of their representatives, such Memorandum will
not, as each such document may be supplemented or amended, contain any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(g) The Company will furnish
Placement Agent, from time to time, with such number of copies of the Memorandum, any exhibits thereto and agreements and documents
referred to therein, as Placement Agent may reasonably request.

 

(h) The Company will advise
Placement Agent promptly of (A) the occurrence of any event or the existence of any condition known to the Company referred
to in Section 2(f) hereof; (B) the receipt by the Company of any communication, stop order or any order from the SEC, any
state securities commissioner or any other domestic or foreign securities or financial regulatory authority or self-regulatory
organization concerning the Offering; and (C) the commencement of any lawsuit or proceeding to which the Company is a party relating
to the Series A Preferred Stock or the Offering. The Company shall make every reasonable effort to prevent the issuance of any
stop order and, if any stop order is issued, to obtain the lifting thereof as promptly as possible.

 

(i)The Company will provide
each offeree the reasonable opportunity to ask questions of, and receive answers from, the officers and employees of the Company
concerning the terms and conditions of the Offering and to obtain any other additional information about the Company and the Series
A Preferred Stock to the extent the officers and employees of the Company possess the same or can acquire it without unreasonable
effort or expense and it is not otherwise confidential or trade secret information. The Company may require appropriate confidentiality
and non-disclosure agreements as it is advised by counsel prior to the disclosure of any information not otherwise contained in
the Memorandum.

 

    	 

    	 

    

 

(j)The Company is not in
default in the performance or observance of any material obligation (A) under its charter or its by-laws, or, to its knowledge,
any indenture, mortgage, contract, purchase order or other agreement or instrument to which the Company is a party or by which
it or any of its property is bound or affected; or (B) with respect to any order, writ injunction or decree of any court of
any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic
or foreign, and, to the Company's knowledge, there exists no condition, event or act which constitutes, nor which after notice,
the lapse of time or both, could constitute a default under any of the foregoing, which in either case would have a material adverse
effect on the current business of the Company.

 

(k)The Company has full
right, power and authority to execute and deliver this Agreement and to perform all of its obligations hereunder. 

 

(l)The authorization, issuance,
sale and delivery of the Securities will not (1) violate any provision of law or statute or any order of any court or other
governmental agency applicable to the Company; or (2) conflict with or result in any breach of any of the terms, conditions
or provisions of, or constitute (with due notice or lapse of time or both) a default under, or result in the creation of any material
lien, security interest, charge or encumbrance upon any of the properties or assets of the Company under its charter or by-laws,
or any indenture, mortgage, lease agreement or other material agreement or instrument to which the Company is a party or by which
it or any of its property is bound or affected except for violations, conflicts, breaches and defaults that would not, individually
or in the aggregate, materially and adversely affect the Company, Placement Agent or any investor in the Offering.

 

(m)The Company will have
prior to the consummation of the Offering all requisite corporate power and authority to issue, sell and deliver the Securities
and such issuances, sales and deliveries will be duly authorized by all requisite corporate action of the Company and when so issued,
sold and delivered the Series A Preferred Stock will be duly and validly issued and outstanding, valid and binding obligations
of the Company, fully paid and nonassessable, with no personal liability attaching to the ownership thereof and will be free and
clear of all liens, charges, claims, encumbrances, restrictions or preemptive or any other similar rights imposed by or through
the Company, except as waived prior to the Closing or as disclosed herein or in the Memorandum, and the Company shall have paid
all taxes, if any, in respect of the issuance thereof. Assuming that the investors meet such suitability standards as are specified
by the Company and the Placement Agent, and the representations and warranties of Placement Agent are accurate as to the method
of offering, the offer and sale of the Series A Preferred Stock will be exempt from the registration requirements of the Securities
Act and the rules and regulations promulgated thereunder and the state “blue sky” laws and the Series A Preferred Stock
will be issued in compliance with all applicable Federal and state securities laws.

 

(n)No permit, consent, approval,
authorization, order of, or filing with, any court or governmental authority is required in connection with the execution and delivery
by the Company of this Agreement or to consummate the Offering other than any that will be made or obtained prior to the consummation
of the Offering, except that the offer and sale of the Securities in certain jurisdictions may be subject to the provisions of
the securities or “blue sky” laws of such jurisdictions and the federal securities laws and certain filings may be
made following the consummation of the Offering.

 

    	 

    	 

    

 

(o)There is no action, suit
or proceeding before or by any United States court or governmental agency or body, now pending or threatened in writing, against
the Company, or any of its properties, which would reasonably be anticipated to result in any material adverse change in the condition
(financial or otherwise) or in the earnings, current business, current business plan as described in the Memorandum, properties
or assets of the Company and its subsidiaries (a “Material Adverse Effect”).

 

(p)The Company has (A) duly
and timely filed all tax returns required to be filed by the Company under applicable law that include or relate to the Company,
its income, assets, payroll, operations or business, which tax returns are true, correct and complete in all material respects;
(B) duly and timely paid, in full, all taxes which are currently due and payable and for which the Company is liable; or (C)
adequately reserved for taxes that have not been paid or are in dispute except as to any events described in this subparagraph
that would not reasonably be expected to have a Material Adverse Effect.

 

(q)The Company, to its knowledge,
is not in default under any agreement, lease, license contract or commitment, whether oral or written including, without limitation,
agreements with employees and consultants (“Company Agreements”) to which the Company is a party or by which any of
its assets are bound, and there is no event known to the Company that, with notice, or lapse of time, or both, would constitute
a default by any party to any Company Agreement or give any party the right to terminate or modify any of the same and the Company
has not received notice that any party to any Company Agreement intends to cancel or terminate any Company Agreement or to exercise
or not to exercise any renewal or extension options under any Company Agreement, except as to any events described in this subparagraph
that would not have a Material Adverse Effect.

 

(r)The Company, to its knowledge,
holds, and is in compliance with, all permits, licenses, registrations and authorizations required by it in connection with the
conduct of the business of the Company as currently conducted under all Federal, state and local laws, rules and regulations (the
“Permits”), except where the failure to be in compliance has not had, and is not reasonably expected to have, a Material
Adverse Effect.

 

(s)The Company’s financial
statements, which may be unaudited, will be furnished upon request to offerees, the Placement Agent, and Participating Dealers.

 

(t)The Company does not
have any liabilities or obligations (whether actual or accrued, accruing or contingent, or otherwise) which, individually or in
aggregate, would be deemed material, other than those set forth in the balance sheet included within the financial statements included
in the Company Data, if any, and those incurred, in the ordinary course of its business.

 

(u)The consummation of the
Offering and the release of the investor funds from the Escrow Account shall be further subject to any other conditions set forth
in the Memorandum or the subscription agreement entered into by each purchaser of Series A Preferred Stock.

 

(v) The Company will be
responsible for and comply with all applicable notification and fee requirements to qualify the offering and sale for exemption
under the state securities or “blue sky” laws of such jurisdiction in which any sales pursuant to the offering may
be transacted and as may otherwise be required or as requested by the Placement Agent provided that, in connection therewith, the
Company shall not be required to qualify as a foreign corporation.

 

3.                 
   Representations and Warranties of the Placement Agent. The Placement Agent represents and warrants to, and
agrees with, the Company as follows:

 

    	 

    	 

    

 

(a)The Placement Agent is
a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it was formed,
with all requisite power and authority to enter into this Agreement and to carry out its obligations hereunder. This Agreement
(i) has been duly authorized, executed and delivered by the Placement Agent, (ii) constitutes a legal, valid and binding obligation
of the Placement Agent, and (iii) subject to applicable bankruptcy, insolvency and other laws affecting the enforceability of creditors'
rights generally, is enforceable as to the Placement Agent in accordance with its terms, specific performance hereof being limited
by general principles of equity and the enforceability of the indemnification provisions hereof.

 

(b)The execution, delivery
and performance of this Agreement by the Placement Agent and the consummation by the Placement Agent of the transactions contemplated
hereby and by the Memorandum will not conflict with or result in the Placement Agent’s breach or violation of any of the
terms or provisions of, or constitute a default in any material respect under, (i) any indenture, mortgage, deed of trust, loan
agreement, lease or other agreement or instrument to which the Placement Agent is a party or to which the Placement Agent or its
property is subject, (ii) the Placement Agent’s charter or its operating agreement or (iii) any statute, judgment, decree,
order, rule or regulation applicable to the Placement Agent of any court or governmental agency or body having jurisdiction over
the Placement Agent.

 

(c)The Placement Agent is,
and at all times through the date of the final sale of the Series A Preferred Stock shall remain, duly registered pursuant to the
provisions of the Securities Exchange Act of 1934, as amended (“Exchange Act”) as a broker-dealer and duly registered
as a broker-dealer in those states in which the Placement Agent is required to be so registered in order to carry out the Offering
as contemplated by the Memorandum; the Placement Agent is, and at all times through the date of the final sale of a Unit shall
remain, a member in good standing of FINRA; the Placement Agent will not re-allow discounts or pay commissions or other compensation
for participation in the distribution of the Offering in the United States to any broker-dealer which is not a member of the FINRA;
the Placement Agent shall act as an independent contractor, and nothing herein shall constitute the Placement Agent an employee
of the Company.

 

(d)In connection with the
offer, offer for sale and sale of the Series A Preferred Stock, the Placement Agent (and its representatives and Participating
Dealers) shall conform to and comply with (i) the provisions of the Rules of Fair Practice of FINRA, (ii) applicable provisions
of federal law, including without limitation the Securities Act, the Exchange Act and the Rules and Regulations, (iii) anti-money
laundering regulations applicable under the USA PATRIOT Act or foreign jurisdictions, and (iv) the State Acts and the rules and
regulations thereunder, and counsel for the Company shall make all such filings as are required pursuant to state securities and
“blue sky” laws, and shall send to the Placement Agent from time to time copies thereof, during the period during which
the Series A Preferred Stock may be offered, offered for sale and sold in various states.

 

(e)The Placement Agent will
use its best efforts to procure subscribers for the Series A Preferred Stock and will conduct the Offering in compliance with the
suitability standards set forth in the Memorandum and with the requirements of Section 4(2) of the Securities Act, Rule 506 of
Regulation D and/or Regulation S, as and to the extent applicable to the Offering; accordingly, at all times through the date of
the final sale of the Series A Preferred Stock, the Placement Agent will have:

 

(i)not
made any untrue statement of a material fact and not omitted to state a material fact required to be stated or necessary to make
any statement made not misleading, to the extent any representations are made by the Placement Agent concerning the Offering or
matters set forth in the Memorandum and Company Data other than those set forth in the Memorandum and Company Data;

 

    	 

    	 

    

 

(ii)not
offered, offered for sale, or sold the Series A Preferred Stock by means of any form of general solicitation or general advertising,
including, but not limited to: (A) any advertisement, article, notice, or other communication mentioning the Series A Preferred
Stock published in any newspaper, magazine or similar medium or broadcast over television or radio; (B) any seminar or meeting,
the attendees of which have been invited by any general solicitation or general advertising; or (C) any letter, circular, notice,
or other written communication, unless the communication is accompanied or preceded by the Memorandum;

 

(iii)prior
to the sale of any of the Series A Preferred Stock, reasonably believed that each subscriber met the suitability and other investor
standards set forth in the Memorandum and the state securities or “blue sky” laws of the applicable jurisdictions,
and the Placement Agent will have prepared and maintained, for its benefit and the benefit of the Company, file memoranda and other
appropriate records substantiating the foregoing;

 

(iv)only
used sales materials which have been approved for use in the Offering by the Company, and refrained from providing any such materials
to any offeree unless such materials were accompanied or preceded by the Memorandum;

 

(v)provided
each offeree, either directly or through a Participating Dealer, with a copy of the Memorandum;

 

(vi)promptly
distributed any amendment or supplement to the Memorandum provided to the Placement Agent by the Company under this Agreement to
persons who had previously received a copy of the Memorandum from the Placement Agent and who the Placement Agent believed continued
to be interested in the Series A Preferred Stock and have included such amendment or supplement in all deliveries of the Memorandum
made after receipt of any such amendment or supplement; and

 

(vii)not
made any representations on behalf of the Company other than those contained in the Company's approved subscription agreement,
nor shall the Placement Agent have acted as an agent of the Company or for the Company in any other capacity, except as expressly
set forth herein.

 

4.                 
   Compensation and Expenses.In consideration of Placement Agent’s services, the Company shall pay
Placement Agent a fee (the “Fee”) to be paid contemporaneously (and as a condition to Closing) at the Closing consisting
of cash and warrants as follows: 

 

(a)
The Placement Agent will be paid a total cash commission of 10% of funds raised from investors introduced by them and
will receive (a) on the first $1,613,375 of total gross proceeds, (i) warrants exercisable for a period of ten (10) years
from the date of issuance, to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A Preferred
Stock sold to investors introduced by them, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period
of ten (10) years from the date of issuance, to purchase a number of shares of Series A Preferred Stock equal to 2.5% of the number
of shares of Series A Preferred Stock sold to investors introduced by them, with a per share exercise price of $1.00, and (b) on
total gross proceeds in excess of $1,613,375, warrants exercisable for a period of ten (10) years from the date of issuance, to
purchase a number of shares of Series A Preferred Stock equal to 10% of the number of shares of Series A Preferred Stock sold to
investors introduced by them, with an exercise price of $1.00 per share. The Company shall have no obligation to compensate any
Participating Dealer for its services in connection with the Offering and all such compensation obligations shall be between the
Placement Agent and the Participating Dealer(s), unless otherwise agreed to by the Company. In the event that the Company consummates
the Merger (as such term is defined in the Term Sheet, dated May 7, 2013, by and between the Company and Hannah Rose Holdings,
LLC), in lieu of the warrants for Series A Preferred Stock and Common Stock described above, the Placement Agent shall receive
warrants exercisable for a number of shares of capital stock equal to the number of shares of capital stock that had such warrants
been exercised, the warrantholder would have received in exchange for the shares of Series A Preferred Stock and Common Stock underlying
the warrants, pursuant to the terms of the definitive Merger documentation.

 

    	 

    	 

    

 

(b) The Company
shall also pay the Placement Agent the fees set forth in Section 4(a) if during the Post-Offering Period (as defined below) any
person or entity contacted by the Placement Agent during the Offering Period and whose name is set forth on a schedule listing
such persons and entities, which schedule shall be provided by the Placement Agent to the Company at the Closing, invests in the
Company (each, a “Post-Closing Investor”), regardless of whether or not such Post-Closing Investor also invested in
the Offering. For purposes hereof, the “Post-Offering Period” shall mean the later of the date that is (i) twenty-four
(24) months after the termination of the Offering Period and (ii) the final Closing of the Offering.

 

(c) In addition,
the Company has previously reimbursed Intuitive Venture Partners, LLC $25,000 for expenses in connection with the Offering.

 

5.                 
   Covenants
of the Company. The Company
covenants and agrees that it will:

  

(a)Comply with all requirements
imposed upon it by the Securities Act, as now and hereafter amended, by the Rules and Regulations from time to time in force, and
by all State Acts, to permit the continuance of offers and sales of the Securities in accordance with the provisions of Section
4(2) of the Securities Act, Rule 506 of Regulation D and/or Regulation S, as and to the extent applicable to the Offering, and
the Memorandum.

 

(b)Until the termination
of the Offering Period, furnish to the Placement Agent information reasonably necessary to keep the Memorandum fair, accurate and
complete in all material respects.

 

(c)If at any time any event
occurs as a result of which the Memorandum would include an untrue statement of a material fact or, in view of the circumstances
under which they were made, omit to state any material fact necessary to make the statements therein not misleading, the
Company will notify the Placement Agent thereof (unless the information shall have been received from the Placement Agent).

 

(d)Provided their subscriptions
are accepted by the Company, issue the Series A Preferred Stock to the holders in accordance with the description of the procedures
as set forth in the Memorandum and the subscription documents to be delivered with the Memorandum.

 

(e)Prepare, execute and
file a Form D (and any and all amendments or supplements thereto) with the SEC in a timely manner and deliver copies thereof to
the Placement Agent, together with copies of all forms (including without limitation, Form Ds) and other documents and/or materials
filed either before or after the Closing, and comply with Regulation D and the State Acts and make any filings required by the
SEC and state securities authorities in a timely manner.

 

    	 

    	 

    

 

(f)The Company will make
available for inspection by the Placement Agent or its authorized representatives, at the Company’s principal office during
normal business hours, any information and documents relating to the business and operations of the Company as the Placement Agent
may reasonably request and as are available to the Company or obtainable by it without unreasonable effort or expense.

 

(g)The Company will apply
the net proceeds from the sale of the Series A Preferred Stock as set forth in the Memorandum.

 

6.                 
   Covenants of Placement
Agent. The Placement Agent covenants and agrees that it will:

 

(a)Comply with all requirements
imposed upon it by the Securities Act, as now and hereafter amended, by the Rules and Regulations from time to time in force, and
by all State Acts, to permit the continuance of offers and sales of the Series A Preferred Stock in accordance with Section 4(2)
of the Securities Act, Rule 506 of Regulation D and/or Regulation S, as and to the extent applicable to the Offering, and to the
Memorandum.

 

(b)Comply with all applicable
rules of the FINRA and any other laws, rules and regulations applicable to broker-dealers.

 

(c)Not offer, offer for
sale or sell any of the Series A Preferred Stock, except and to the extent any such offer, offer for sale or sale shall not render
unavailable the exemptions from registration and qualification requirements of the Securities Act and the State Acts relied upon
with respect to the offering and sale of the Series A Preferred Stock contemplated by this Agreement.

 

7.                 
   Conditions of Closing. The purchase of, and payment for, the Series A Preferred Stock at the Closing shall
be subject to the continuing accuracy of the representations and warranties of the Company and the Placement Agent as of the date
hereof and as of the Closing, to the performance by the Company and Placement Agent of their respective obligations hereunder,
and to the following conditions:

 

(a)The Placement Agent's
obligations as provided herein shall be subject to the accuracy of the representations, warranties and covenants of the Company
herein contained as of the date hereof and as of the date of the Closing, and to the performance by the Company of its obligations
hereunder to be performed.

 

(b)At the Closing, if any,
the Company shall:

 

(1)Accept subscriptions
of qualifying potential purchasers that the Company reasonably believes to be qualified investors under Regulation D and/or Regulation
S and the State Acts and on the Agreed List, in accordance with the Memorandum. Notwithstanding the foregoing, the Company may
reject the subscription of any qualifying purchaser if (A) a potential purchaser is a competitor, or an affiliate of a competitor,
of the Company, or (B) the Company deems it prudent and in the best interests of the Company to reject such subscription; provided
further, that the acceptance of any subscription by the Company may not be unreasonably withheld. The Company agrees that if the
Company rejects the subscription of a qualifying purchaser for the reasons set forth in clause (B) above (each, a “Rejected
Purchaser”), at the Closing, or any closing held by the Company, the Company shall pay the Placement Agent a cash payment
in the amount of one (1%) percent of the aggregate gross proceeds that the Company would have received if it would have accepted
the subscription of the Rejected Purchaser at such closing.

 

    	 

    	 

    

 

(2)Instruct the Escrow Agent,
jointly with the Placement Agent, to release the proceeds of the Offering to the Company, net of compensation payable to the Placement
Agent and any rejected subscription amounts to be returned to subscribers.

 

(3)Provide for the issuance
of certificates representing the Securities, which certificates will be delivered to subscribers within ten (10) business days
of the Closing, or as otherwise described in the Memorandum.

 

(c)At the Closing, if any,
the Placement Agent shall:

 

(1)Deliver to the Company
all subscription agreements that the Company agrees are acceptable.

 

(2)Instruct the Escrow Agent
to release the proceeds of the Offering to the Company, net of compensation payable to the Placement Agent and any rejected subscription
amounts to be returned to subscribers.

 

(3)Receive from the Company,
or give assignment instructions for, all compensation payable to the Placement Agent.

 

8.                 
   Indemnification. 

 

(a)The
Placement Agent and each of the Participating Dealers, severally and not jointly (each, an “Agent Party”), agree to
indemnify and hold the Company and the directors, officers, employees, agents, attorneys, shareholders and control persons (as
defined under federal and state securities laws) of the Company, and the respective heirs, personal representatives and assigns
of each of the foregoing (collectively, the “Company Indemnified Persons”) harmless from and against any loss, liability,
claim, damage, cost and expense (collectively, “Damages”, including, but not limited to, reasonable attorneys’
fees, experts’ fees and other expenses reasonably incurred in investigating, preparing or defending against any litigation,
commenced or threatened, or any claim whatsoever based upon) to which the Company Indemnified Persons may become subject, under
the Securities Act or otherwise, insofar as such Damages arise solely out of: (i) any material breach of any representation, warranty,
agreement or covenant under this Agreement or the Dealer Agreement by such Agent Party, (ii) any untrue statement or alleged untrue
statement of any material fact contained in the Memorandum, arising out of or based upon the omission to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading in each case to the extent, but
only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Memorandum
in reliance upon and in conformity with information furnished to the Company by such Agent Party, (iii) any statement made in
a writing by such Agent Party containing an untrue statement or alleged untrue statement of any material fact or the omission
or alleged omission to state a material fact required to be stated or necessary to make the statements not misleading, unless
such statements or omissions are made in reliance upon or in conformity with statements made or information provided by the Company
(including the Company Data) which have been approved by the Company for dissemination to prospective investors, and/or (iv) any
amount paid in settlement of any litigation, commenced or threatened, or of any claim based upon any of the matters under (i)
through (iii) (including, but not limited to, expenses reasonably incurred in investigating, preparing or defending against any
such litigation or claim); provided, however that the Agent Parties shall not be liable to any Company Indemnified Person to the
extent that any Damages, or any actions in respect thereof, arise out of or are based upon an untrue statement of material fact
or omission of material fact made in the final Memorandum, which has been approved by the Company for dissemination to prospective
investors, in reliance upon and in conformity with information furnished to the Placement Agent by or on behalf of the Company
Indemnified Person. Notwithstanding the foregoing, no Agent Party shall be required to indemnify the Company for any amounts in
excess of the aggregate commissions actually received by such Agent Party from the sale of Series A Preferred Stock. 

 

    	 

    	 

    

 

If
for any reason, the foregoing indemnification is unavailable to any Company Indemnified Persons, then each Agent Party shall contribute
to the amount paid or payable by any such Company Indemnified Person as a result of such loss, claim, damage or liability in such
proportion as is appropriate to reflect the relative fault of such Agent Party to other Agent Parties and any Company Indemnified
Person; provided, however, that in no event shall the amount contributed by any Agent Party exceed the aggregate
commissions actually received by such Agent Party from the sale of Series A Preferred Stock. 

 

Promptly
after a Company Indemnified Person receives notice of the commencement of any action, claim, proceeding or investigation (“Action”),
such Company Indemnified Person, if a claim in respect thereof is to be made against an Agent Party under this Section 8(a), will
notify such Agent Party of the commencement thereof. The omission to so notify such Agent Party will relieve such Agent Party from
any liability which it may have to any Company Indemnified Person under this Section 8(a) if the Agent Party has been prejudiced
in asserting, or shall have lost the right to assert, a legal defense by reason of such omission. Such Agent Party will be entitled
to participate in, and, to the extent that it may wish, to assume the defense thereof subject to the provisions herein stated,
with counsel reasonably satisfactory to the Company Indemnified Person. The Company Indemnified Person will have the right to employ
separate counsel in any such Action and to participate in the defense thereof but the fees and expenses of such counsel will be
at the expense of the Company Indemnified Person if the Agent Party has assumed the defense of the Action with counsel reasonably
satisfactory to the Company Indemnified Person. No settlement of any Action against a Company Indemnified Person for which indemnification
from an Agent Party is sought will be made without the consent of such Agent Party (which consent shall not be unreasonably withheld,
conditioned or delayed).

  

(b)The Company agrees to
indemnify and hold the Placement Agent and Participating Dealers, the directors, officers, employees, agents, attorneys, shareholders
and control persons (as defined under federal and state securities laws) of the Placement Agent and the Participating Dealers,
and the respective heirs, personal representatives and assigns of each of the foregoing (collectively, the “Agent Indemnified
Persons”) harmless from and against any Damages to which the Agent Indemnified Persons may become subject, under the Securities
Act or otherwise, insofar as such Damages arise out of or relate to: (i) any material breach of any representation, warranty, agreement
or covenant under this Agreement by the Company, (ii) any untrue statement or alleged untrue statement of any material fact contained
in the final Memorandum or the final Company Data which has been approved by the Company for distribution to prospective investors,
or arising out of or based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading in each case , (iii) any statement made in a writing by the Company
that is delivered by the Company to a prospective investor (or any such statement made in writing by the Company that has been
approved by the Company for distribution to prospective investors) containing an untrue statement or alleged untrue statement of
any material fact or the omission or alleged omission to state a material fact required to be stated or necessary to make the statements
not misleading, and/or (iv) any amount paid in settlement of any litigation, commenced or threatened, or of any claim based upon
any of the matters under (i) through (iii) (including, but not limited to, expenses reasonably incurred in investigating, preparing
or defending against any such litigation or claim); provided, however, that the Company shall not be liable to any
Agent Indemnified Person to the extent that any Damages, or any actions in respect thereof, arise out of or are based upon an untrue
statement of material fact or omission of material fact made in the Memorandum in reliance upon and in conformity with information
furnished to the Company by or on behalf of the Agent Indemnified Person. The liability for indemnification shall have a limit
not to exceed the gross offering proceeds for shares of Preferred Stock sold by the Company to investors introduced to the Company
by Placement Agent in this offering.

 

    	 

    	 

    

 

If for any reason,
the foregoing indemnification is unavailable to any Agent Indemnified Persons, then the Company shall contribute to the amount
paid or payable by any such Agent Indemnified Persons as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect the relative fault of the Company and any Agent Indemnified Person; provided, however,
that in no event shall the amount contributed by any Agent Indemnified Person exceed the aggregate commissions actually received
by such Agent Indemnified Person from the sale of Series A Preferred Stock. The liability for indemnification shall have a limit
not to exceed the gross offering proceeds for shares of Preferred Stock sold and received by the Company in this offering.

 

Promptly after an Agent
Indemnified Person receives notice of the commencement of any Action, such Agent Indemnified Person, if a claim in respect thereof
is to be made against the Company under this Section 8(b), will notify the Company of the commencement thereof. The omission to
so notify the Company will relieve the Company from any liability which it may have to any Agent Indemnified Person under this
Section 8(b) if the Company has been prejudiced in asserting, or shall have lost the right to assert, a legal defense by reason
of such omission. The Company will be entitled to participate in, and, to the extent that they may wish, to assume the defense
thereof subject to the provisions herein stated, with counsel reasonably satisfactory to such Agent Indemnified Person. The Agent
Indemnified Person will have the right to employ separate counsel in any such Action and to participate in the defense thereof
but the fees and expenses of such counsel will be at the expense of the Agent Indemnified Person if the Company has assumed the
defense of the Action with counsel reasonably satisfactory to the Agent Indemnified Person. No settlement of any Action against
an Agent Indemnified Person for which indemnification from the Company is sought will be made without the consent of the Company
(which consent shall not be unreasonably withheld, conditioned or delayed).

 

9.                 
   Representations,
Indemnities and Agreements to Survive Sale and Payment. The respective representations, indemnities, warranties, covenants
and other agreements of the Company and the Placement Agent set forth in or made pursuant to this Agreement, shall remain in full
force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any Agent Indemnified
Person or Company Indemnified Person, and shall survive closing, delivery of, and payment for the Series A Preferred Stock.

 

10.                 
   Termination
of Agreement. Notwithstanding any of the terms and provisions hereof, this Agreement may be terminated by the Placement Agent
based on a material breach of this Agreement by the Company. The Placement Agent shall give fifteen (15) days' prior written notice
to the Company of such material breach, and the Company shall have fifteen (15) days to cure such material breach before the Placement
Agent may terminate the Agreement. In the event the Placement Agent reasonably determines that it is unsatisfied with the results
of its due diligence investigation or that the Series A Preferred Stock is not marketable, notwithstanding its best efforts to
sell the Series A Preferred Stock, the Placement Agent may terminate this Agreement upon written notice to the Company.

 

This Agreement shall
terminate automatically (an "Automatic Termination") if at any time the Placement Agent or any Participating Dealer ceases
to be duly registered pursuant to the provisions of the Exchange Act as a broker-dealer and duly registered as a broker-dealer
in those states in which the Placement Agent is required to be so registered in order to carry out the Offering as contemplated
by the Memorandum or the Placement Agent ceases to be a member in good standing of the FINRA.

 

    	 

    	 

    

 

In the event of an
Automatic Termination or any termination of this Agreement by the Placement Agent, the Placement Agent shall be entitled to any
fees and compensation to which it was entitled under Section 4 only as of the date of such termination.

 

The Company may terminate
this agreement in its sole discretion by providing ten (10) days written notice to the Placement Agent. Upon such a termination
by the Company, the Placement Agent shall be entitled to any fees and compensation that it was entitled to receive under Section
4 hereof as of the date of termination and for the three month period following termination for investments made in the Company
by those investors sourced by the Placement Agent.

 

Additionally, Sections
8, 9, 10, 11 and 12 shall survive any termination or expiration of this Agreement and shall survive closing, delivery of, and payment
for the Series A Preferred Stock.

 

11.                 
 Notices.
All notices, requests, demands or other communications with respect to this Agreement shall be in writing and shall be personally
delivered or mailed, postage prepaid, by certified mail, or delivered by facsimile or electronic mail (“e-mail”) or
a nationally recognized express courier service, charges prepaid, to the Company or Placement Agent at the addresses set forth
in this Agreement (or such other addresses as the parties may specify from time to time in accordance with this section). Any such
notice shall, when sent in accordance with the preceding sentence, be deemed to have been given and received, on the earliest of:
(i) on the day personally delivered including by facsimile or e-mail (with confirmation of receipt), (ii) on the third day following
the date mailed, or (iii) twenty-four hours after shipment by such courier service.

 

12.                 
 Miscellaneous Provisions.

 

(a)Governing
Law. This Agreement shall be governed by, subject to, and construed in accordance with the laws of the state of Delaware without
regard to such state’s conflicts of law principles.

 

(b)Severability.
If any portion of this Agreement shall be held invalid or inoperative, then, so far as is reasonable and possible (i) the remainder
of this Agreement shall be considered valid and operative, and (ii) effect shall be given to the intent manifested by the portion
held invalid or inoperative.

 

(c)Modification
or Amendment. This Agreement may not be modified or amended except by written agreement executed by the parties hereto.

 

(d)Number
and Gender of Words. Whenever the context so requires, the masculine shall include the feminine and neuter, and the singular
shall include the plural, and conversely.

 

(e)Other
Instruments; Counterparts. The parties hereto covenant and agree that they will execute such other and further instruments
and documents as are or may become necessary or convenient to effect and carry out the terms of this Agreement. This Agreement
may be executed by facsimile signatures or signatures delivered via e-mail, and in multiple counterparts, each of which shall be
deemed an original. It shall not be necessary that each party executes each counterpart, or that any one counterpart be executed
by more than one party so long as each party executes at least one counterpart.

 

(f)No Partnership.
The Placement Agent is not a principal of or a partner with, or does not control in any way, the Company or its employees, except
in such relationships disclosed in the Memorandum, subscription documents, or other offering materials.

 

    	 

    	 

    

 

(g)Limitation
on Services. The Placement Agent shall not be obligated to provide advice or perform services to the Company that are not specifically
addressed in this Agreement. The Company hereby acknowledges that the Placement Agent is not a fiduciary of the Company and that
the Placement Agent makes no representations or warranties regarding the Company’s ability to secure financing, whether now
or in the future. The obligations of the Placement Agent described in this Agreement consist solely of commercially reasonable
best efforts services to the Company, and in no event shall the Placement Agent be required to act as the agent of the Company
or to provide legal or accounting services. All final decisions with respect to acts of the Company or its affiliates, whether
or not made pursuant to or in reliance upon information or advice furnished by the Placement Agent hereunder, shall be those of
the Company or such affiliates, and the Placement Agent shall under no circumstances be liable for any expense incurred or loss
suffered by the Company as a consequence of such decisions.

 

(h)Announcements.
Before the Company releases any information referring to the Placement Agent’s role
under this Offering or uses Placement Agent’s name in a manner which may result in public dissemination thereof, the Company
shall furnish drafts of all documents or prepared oral statements to Placement Agent for comments, and shall not release any information
relating thereto without the prior written consent of the Placement Agent. Notwithstanding the foregoing, nothing herein shall
prevent the Company from releasing any information to the extent that such release is required by law, rule or regulation. The
Company agrees that, following the completion of the Offering, the Placement Agent shall have the right to place “tombstone”
style advertisements describing its services to the Company hereunder (i) in financial and other newspapers and journals or (ii)
on the Placement Agent’s website or in other marketing materials of the Placement Agent, at the Placement Agent’s
cost provided that Placement Agent will submit a copy of any such advertisements to the Company for its prior approval, which
approval shall not be unreasonably withheld.

 

 

(i)Assignment.
This Agreement shall not be assignable by any party to this Agreement without the express prior written consent of the other party
to the Agreement, and in the event of an attempted assignment by one party to this Agreement without such consent, such attempted
assignment shall be void and without effect.

 

(j)Parties.
This Agreement shall be binding upon and inure solely to the benefit of the parties hereto, their respective successors and any
permitted assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or
in respect of or by virtue of this Agreement or any provision herein contained, except that the Participating Dealers shall be
a third party beneficiary of the provisions of Section 8(b) hereof. No purchaser of any of the Series A Preferred Stock shall be
construed a successor, representative or assignee by reason of such purchase.

 

(k)Entire
Agreement. This Agreement contains the entire understanding between the parties and supersedes any prior or contemporaneous
understandings or written or oral agreements between them respecting the subject matter hereof.

 

(l) Dispute
Resolution; Attorneys’ Fees. If a dispute or claim shall arise with respect to any of the terms or provisions of this
Agreement, or with respect to the performance by any of the parties under this Agreement, then the parties agree to submit the
dispute to binding and non-appealable arbitration in a venue located in New York, New York in accordance with the rules of the
American Arbitration Association (“AAA”). In connection with any such arbitration, each side will be limited to a maximum
of three (3) days of argument (including rebuttal), and the parties agree in good faith to minimize discovery burdens (e.g., confine
the scope to actual areas in dispute and limit the topics and number of pages on which information is requested to matters directly
relevant). The prevailing party shall be reimbursed by the nonprevailing party for all reasonable attorney's fees and costs (including
all arbitration costs) incurred by the prevailing party in resolving such dispute. Any award rendered in arbitration may be enforced
in any court of competent jurisdiction. Notwithstanding the foregoing, any action by either party to obtain specific performance
of any provision of this Agreement by the other party may be brought in any appropriate judicial forum.

  

[Remainder of this page intentionally
left blank.]

 

    	 

    	 

    

If the foregoing is
in accordance with your understanding, please sign and return to us a counterpart hereof, whereupon this Agreement shall constitute
a binding agreement between the Placement Agent and the Company.

 

	 	NEUROTROPE BIOSCIENCE, INC.	 
	 	 	 	 
	 	 	 	 
	 	By:  	/s/ Jim New	 
	 	Name: Jim New, Ph.D.	 
	 	Title: Chief Executive Officer	 

 

	ACCEPTED AND AGREED TO:	 
	 	 
	EDI Financial, Inc.  	 
	 	 
	 	 
	By:
    /s/ James Hintz 	 
	 	      
	Name:
James Hintz	 
	Title: Principal	 
	Date: June 25, 2013

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]